) announced that it dosed its first patient in its phase I study
evaluating candidate EC1456, for the treatment of advanced solid
We note that EC1456 is a folate receptor (FR)-targeting
The phase I study is divided into parts. The two-division
study is an open-label, multicenter, non-randomized,
dose-escalation study which will evaluate EC1456 in advanced
Evaluation of the maximum tolerated dose (MTD) will be carried
out in the first part of the study. The first will also evaluate
the recommended dose for the phase II study. The second part of
the study will evaluate the efficacy of EC1456 in patients with
select cancers known to express the folate receptor (FR) with all
target lesions positive for FR and treated with MTD.
30 patients will be enrolled in the first part of the study
while 10 patients each with advanced solid cancer indication,
will be included in the second part of the study.
The first part of the study will enroll patients with
metastatic or locally advanced solid tumors who have failed to
respond to standard therapy, if available. The second part will
enlist patients with the advanced solid cancer indication, who
have not received more than two chemotherapies in the past.
The primary endpoint of the study is to evaluate MTD and a
recommended dose for phase II of the study. Identification of the
safety profile of EC1456, efficacy and pharmacokinetic analysis,
as well as the correlation between baseline folate expression
measured by etarfolatide scans and antitumor activity of EC1456
constitute the secondary endpoints of the study.
We note that an investigational new drug application for
EC1456 was accepted by the U.S. Food and Drug Administration
(FDA) in the third quarter of 2013.
Endocyte continues to progress in developing its small
molecule drug conjugates portfolio. Endocyte currently carries a
Zacks Rank #3 (Hold). Some better-ranked stocks include
Aeterna Zentaris Inc.
Jazz Pharmaceuticals plc
). All these stocks carry a Zacks Rank #1 (Strong Buy).
AETERNA ZENTARS (AEZS): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
ENDOCYTE INC (ECYT): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
To read this article on Zacks.com click here.